Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast

MT Newswires Live

07/10

Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.

Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.

The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2650907896"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2650907896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2650907896?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 14:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650907896","market":"nz","top_or_hot":-1,"title":"Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.</p><p>Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.</p><p>The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast's Fiscal Fourth Quarter Net Revenue from MSC Therapy Product Sales Beats Jefferies Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 14:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.</p><p>Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.</p><p>The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650907896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650907896","pubTimestamp":1783665422,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited","MSC":"新濠影汇"},"translate_title":"Mesoblast 第四财季 MSC Therapy 产品销售净收入超出 Jefferies 预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5,"MSC":1.5},"content_text":"Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}